Enhanced Type 2 Immune Reactions by Increased IL-22/IL-22Ra1 Signaling in Chronic Rhinosinusitis With Nasal Polyps

Dong-Kyu Kim,1 Ara Jo,2 Hee-Suk Lim,3 Jin Youp Kim,1 Kyoungh Mi Eun,3 Jayoung Oh,3 Joon Kon Kim,1 Seong-Ho Cho,2 Dae Woo Kim*3

1Department of Otorhinolaryngology-Head and Neck Surgery, Hallym University Chuncheon Sacred Heart Hospital and Institute of New Frontier Research, Hallym University College of Medicine, Chuncheon, Korea
2Division of Allergy-Immunology, Department of Internal Medicine, University of South Florida Morsani College of Medicine, Tampa, FL, USA
3Department of Otorhinolaryngology-Head and Neck Surgery, Seoul Metropolitan Government-Seoul National University Boramae Medical Center, Seoul, Korea

ABSTRACT

Purpose: Recent studies have revealed the pathogenic role of interleukin (IL)-22 in atopic dermatitis and asthma. However, little is known about the role of IL-22 in the pathophysiology of chronic rhinosinusitis with nasal polyps. We aimed to investigate the expression of IL-22 and its pathogenic function in type 2 immune reactions of nasal polyps (NP).

Methods: Protein levels of inflammatory mediators were determined by multiplex immunoassay, and principal component analysis (PCA) was performed. Immunofluorescence analysis and mast cell culture were used to determine the cellular sources of IL-22. Normal human bronchial epithelial (NHBE) cells were stimulated using IL-22 in combination with diverse cytokines, and thymic stromal lymphopoietin (TSLP) was measured.

Results: IL-22 expression was not up-regulated in NP compared with control tissues, but IL-22-high NP revealed distinct features characterized by type 2 inflammatory cytokines such as chemokine (C-C motif) ligand (CCL)-11, CCL-24, and IL-5 on the PCA. Additionally, IL-22 positively correlated with type 2 immune mediators and the disease severity in NP. For the localization of the cellular sources of IL-22 in eosinophilic NP, it was expressed in cells mostly composed of eosinophil peroxidase-positive cells and partially of tryptase-positive cells. The human mast cell line, LAD2 cells, released IL-22 mediated by immunoglobulin E. Moreover, IL-22 receptor subunit alpha-1 (IL-22Ra1) expression was significantly increased in NP. IL-22Ra1 was up-regulated with poly(I:C) stimulation in NHBE cells. Furthermore, TSLP production was enhanced when stimulated with a combination of IL-13, poly(I:C), and IL-22. Treatment with anti-IL-22Ra1 also inhibited IL-22-induced enhancement of TSLP production.

Conclusion: IL-22 was associated with type 2 inflammatory reactions in NP. The IL-22/IL-22Ra1 axis was enhanced and might be involved in type 2 inflammatory reactions via TSLP production in NP.

Keywords: Interleukin-22; biomarkers; thymic stromal lymphopoietin; sinusitis; eosinophils; mast cells; nasal polyps; immunoassay; fluorescent antibody technique
INTRODUCTION

Chronic rhinosinusitis (CRS) is characterized by chronic inflammation of the paranasal sinus mucosa that persists for at least 12 weeks. Currently, the phenotype of CRS is classified into 2 groups: CRS with nasal polyps (CRSwNP) and CRS without nasal polyps (CRSsNP), depending on the presence or absence of nasal polyps (NP) during endoscopic examination. Endotypes can be classified according to the immunological patterns within the same phenotype of CRS. To date, several studies have demonstrated that a number of inflammatory markers and various immune cells have been engaged in the pathogenesis of CRS. However, different phenotypes of CRS show a very similar endotype, or its different endotypes are often presented in a single clinical phenotype. Thus, such disease heterogeneity in patients with CRS remains poorly understood.

Interleukin (IL)-22 is a member of the IL-10 family of cytokines and its signaling pathway plays crucial roles in regulating host defense, tissue homeostasis, and inflammation at mucosa barrier surface. Until now, signaling of IL-22 through its receptor (IL-22R) is known to promote antimicrobial immunity, inflammation, and tissue repair. In addition, IL-22 is also produced by various inflammatory cells, including Th1, Th2, Th17, Th22 cells, natural killer cells, and type 3 innate lymphoid cells, whereas IL-22R is expressed on epithelial cells rather than immune cells. However, several studies demonstrated that IL-22 plays a key role in the pathogenicity of allergic diseases. Recent studies showed that IL-22/IL-22R signaling regulates the pathogenesis of CRSwNP via alteration in MUC1 expression. Therefore, in this study, we aimed to investigate the expression level of IL-22 and its pathogenic function in patients with CRSwNP.

MATERIALS AND METHODS

Patients and tissue samples

Sinosal and NP tissues were obtained from patients with CRS during routine functional endoscopic sinus surgery. All participants provided written informed consent prior to the study, which was approved by the Internal Review Board of Seoul National University Hospital, Boramae Medical Center (No. 30-2017-78). CRS diagnosis was made based on history taking, physical examination, nasal endoscopic exam, and computed tomography (CT) findings of the sinuses according to the 2012 European position paper on rhinosinusitis and NP guidelines. Exclusion criteria are as follows: (1) age younger than 18 years; (2) history of receiving treatment with antibiotics, systemic or topical corticosteroids, or other immune-modulating drugs during 4 weeks prior to surgery; and (3) having been diagnosed with unilateral rhinosinusitis, antrochoanal polyp, allergic fungal rhinosinusitis, cystic fibrosis, or immotile ciliary disease. Control tissues were obtained from patients without any sinonasal diseases during other types of rhinologic surgeries such as skull base and lacrimal duct surgeries. Uncinate process mucosal tissues were obtained, each from control subjects and patients with CRSsNP or CRSwNP; NP tissues in patients with CRSwNP were obtained for evaluation. As previously described, each tissue was divided into 3 parts: one was fixed in 10% formaldehyde and embedded in paraffin for histological analysis, another was immediately frozen and stored at −80°C for subsequent isolation of mRNA, and the third was submerged in 1 mL phosphate-buffered saline supplemented with 0.05% Tween-20 (Sigma-Aldrich, St. Louis, MO, USA) and 1% PIC (Sigma-Aldrich) per 0.1 g of tissue. Then, the third samples were homogenized with a mechanical homogenizer at 1,000 rpm on ice for 5
minutes. After homogenization, the floating materials were centrifuged at 3,000 rpm for 10 minutes at 4ºC, and the supernatants were separated and stored at ~80ºC for further analysis of cytokines and other inflammatory mediators. The atopic status of the study subjects was evaluated using the ImmunoCAP® assay (ThermoFisher Scientific, Waltham, MA, USA) to detect specific Immunoglobulin E (IgE) antibodies against 6 mixtures of common aeroallergens (house dust mites, molds, trees, weeds, grass pollen, and animal danders). Subjects were considered atopic if the allergen-specific IgE level was greater than 0.35 KU/L to more than 1 allergen.24 An asthmatic patient was defined as one who experienced chronic airway symptoms (dyspnea, cough, wheezing, and/or sputum) and reversible airflow limitation and had forced expiratory volume in 1 second increased by ≥ 12% or 200 mL after using a bronchodilator or a methacholine provocation test result of PC20 ≤ 16 mg/mL. Disease severity was evaluated by CT images using the Lund-Mackay scoring system. Patient characteristics are presented in Supplementary Table S1.

**Quantitative real-time polymerase chain reaction (qRT-PCR) analysis**

Total RNA was extracted from tissue samples using the TRI reagent (Invitrogen, Carlsbad, CA, USA). The 1 µg of total RNA was reversely transcribed into cDNA using the cDNA Synthesis Kit (amfiRivert Platinum cDNA Synthesis Master Mix; GenDEPOT, Katy, TX, USA). The qRT-PCR was performed. Analysis of IL-22 receptor subunit alpha-1 (IL-22Ra1; Hs00222035_m1), IL-22Ra2 (Hs00364814_m1), and glyceraldehyde 3-phosphate dehydrogenase (GAPDH; Hs02758991_g1) was performed using pre-developed assay reagent kits of primers and probes from TaqMan assays (Life Technologies Korea, Seoul, Korea). Pre-developed assay reagent kits containing primers and probes were purchased from Applied Biosystems (Foster City, CA, USA). The expression of GAPDH was used as an internal control for normalization. Cycling conditions are as follows: 95°C for 5 minutes, followed by 60 cycles at 95°C for 15 seconds, 60°C for 20 seconds, and 72°C for 20 seconds. To analyze the data, Sequence Detection Software version 1.9.1 (Applied Biosystems) was utilized. Relative gene expression was calculated using the comparative $2^{-\Delta\Delta CT}$ method.

**Measurement of inflammatory mediators in tissue homogenates**

As previously described,25,26 the protein concentrations of tissue extracts were determined using the Pierce 660nm Protein Assay Kit (ThermoFisher Scientific) and samples were thawed at room temperature and vortexed for thorough mixing. Tissue homogenates were then assayed for periostin proteins by using commercially available enzyme-linked immunosorbent assay (ELISA) kits (R&D Systems, Minneapolis, MN, USA). Multiple cytokine analysis kits (IL-1α, IL-1β, IL-5, IL-6, IL-10, IL-13, IL-17A, IL-22, IL-23, IL-33, chemokine [C-C motif] ligand [CCL]-11, CCL-24, chemokine [C-X-C motif] ligand [CXCL]-1, CXCL-2, CXCL-8, interferon (IFN)-γ, myeloperoxidase, transforming growth factor-β, S100A8, glycoprotein130, and B cell activating factor) were obtained from R&D Systems (Cat. No. LMSAHM), and data were collected using Luminex 100 (Luminex, Austin, TX, USA). Data analysis was performed using the MasterFlex QT version 2.0 (MiraBiio, Alameda, CA, USA). The levels of total IgE, Staphylococcal enterotoxins (SE)-specific IgE (SEA, SEB, and SEC), and eosinophil cationic protein (ECP) in nasal tissue homogenates were measured using the ImmunoCAP® assay (ThermoFisher Scientific). All assay procedures mentioned were run in duplicate according to the manufacturer’s protocol. All the protein levels in the tissue homogenate were normalized to the concentration of total protein.
**Immunofluorescence analysis**
To verify the cellular source of IL-22 in NP tissues, immunofluorescence analysis was conducted using primary antibodies directed against anti-IL-22 (1:100; Abcam, Cambridge, MA, USA), anti-mast-cell tryptase (1:500; Abcam), anti-eosinophil peroxidase (EPX) (1:200; Abcam), and anti-human neutrophil elastase (HNE) (1:500; Abcam). After 24 hours of incubation of primary antibodies at 4°C, the secondary antibody Alexa Fluor 488-conjugated goat anti-mouse IgG (1:1,000; Abcam) or Cy3-conjugated goat anti-rabbit (1:500; Abcam) was incubated for 1 hour at room temperature. Then, the nuclei were stained with DAPI (4',6-diamidino-2-phenylindole) (1:1,000; Sigma-Aldrich) for 2 minutes. The tissues were mounted with Fluoroshield Mounting Medium (ab104135; Abcam). Fluorescent images were obtained using the CELENA® S Digital Fluorescence Imaging System (Logos Biosystems, Annandale, VA, USA). The proportion of IL-22-positive cells on each of the tryptase, EPX, and HNE-positive cells was calculated and analyzed in 3 randomly selected fields, and non-specific signals were excluded.

**Human mast cell culture and measurement of cytokine production**
LAD2 mast cells were cultured in serum-free media (StemPro-34 SFM; ThermoFisher Scientific) supplemented with 2 mM L-glutamine, 100 U/mL penicillin, 50 µg/mL streptomycin, and 100 ng/mL stem cell factor (SCF). Cell suspensions were cultured at a density of 10^5 cells/mL, and were maintained at 37°C and 5% CO₂. Sensitized cells were suspended at 5 × 10^4 cells/mL with biotin-conjugated IgE protein (0.5 µg/mL, ABIN457505; Antibodies-online, Aachen, Germany) in fresh media (without SCF) overnight and pre-treated with recombinant human IL-4 (10 ng/mL, 200-04; PeproTech, Philadelphia, PA, USA), recombinant human IL-13 (10 ng/mL, 200-13; PeproTech), or SEB (5 ng/mL; List Biologic Laboratories, Campbell, CA, USA) for 1 hour. Cells were then treated with 0.5 µg/mL streptavidin (S4762; Sigma-Aldrich) for 4, 8, and 24 hours at 37°C. Secreted IL-22 was measured in cell supernatants using the ELISA kit according to the manufacturer’s instructions (R&D Systems). The detection limit for the assay was 31.3 pg/mL.

**Human bronchial epithelial cell culture**
Normal human bronchial epithelial (NHBE) cells were purchased from Lonza (CC-2540; Basel, Switzerland) and cultured in BEGM™ bronchial epithelial growth medium (CC-3170; Lonza) at 37°C in a humidified environment containing 5% CO₂. NHBE cells were plated on 12-well culture plates coated with 6-10 µg/cm² collagen (C8919; Sigma-Aldrich) and were grown to 80% confluence. Before treatment, NHBE cells were maintained in BEGM in the absence of hydrocortisone for at least 2 days. For IL-22Ra1 expression after stimulation of major cytokines and poly(I:C), NHBE cells were treated with recombinant human IL-4 (100 ng/mL; R&D Systems), IL-13 (100 ng/mL; R&D Systems), IL-17A (100 ng/mL; R&D Systems), IFN-γ (100 ng/mL; R&D Systems), and poly(I:C) (5 µg/mL; InvivoGen, San Diego, CA, USA). Supernatants were removed after 24 hours of stimulation and cells were used for RNA extraction. For TSLP measurement, NHBE cells were stimulated with recombinant human IL-4 (100 ng/mL; R&D Systems), IL-13 (100 ng/mL; R&D Systems), IL-22 (1 or 10 or 100 ng/mL; R&D Systems) for 72 hours. Additionally, in each experiment, NHBE cells were stimulated with poly(I:C) (5 µg/mL; InvivoGen) 1 hour after treatment with IL-4, IL-13, and/or IL-22. Anti-IL-22Ra1 (2.5 µg/mL; R&D Systems) was added to confirm the reversibility of IL-22-induced thymic stromal lymphopoietin (TSLP) production. Cell culture supernatants were collected and used for measuring TSLP with the ELISA (R&D Systems).
Statistical analysis
Statistical analyses were performed using GraphPad Prism software 7.0 (GraphPad Software Inc., La Jolla, CA, USA). Data were analyzed with Mann-Whitney U and Kruskal-Wallis tests with Dunn’s multiple comparison test. Correlations were tested by Spearman’s rank correlation coefficients. The Pearson correlation test was also used to determine variable relationships. If the data were not normally distributed, the Spearman correlation coefficient was utilized. The significance level was set at an α value of 0.05. Factor analysis based on principal component analysis (PCA) was used to describe the patterns of inflammatory mediators in varying IL-22 concentrations (interquartile range).

RESULTS
Expression of IL-22 in CRS
ELISA assays were performed to examine the expression of IL-22 at protein levels. The expression level of IL-22 was significantly increased in CRSsNP compared to control and CRSwNP, whereas there was no significant difference in IL-22 expression between control and CRSwNP (Fig. 1A). Next, to determine the influence of IL-22 expressions on the pathogenesis of NP development, we performed exploratory factor analysis using PCA according to the concentration of IL-22 expression.

The PCA retained 9 components, accounting for 68.6% of the overall variance in the data (Supplementary Table S2). On the PCA plot, the first and second components accounted for 14.9% and 12.1% of the variance in the dataset, respectively, but there were overlapping patterns of inflammatory mediators according to the IL-22 concentration (Fig. 1B). However, distinct differences were observed in the third component which accounted for 10.5% of the variance in the dataset (Fig. 1C). NP with very high IL-22 levels seemed distinguishable from the other groups by type 2 inflammatory markers such as CCL-11, CCL-24, and IL-5.

Correlations between IL-22 expression and inflammatory markers in CRS
To elucidate the role of IL-22 in CRSwNP, we evaluated the correlation between IL-22 and other major inflammatory mediators (Fig. 2A). We found that there was a positive correlation between IL-22 expression and type 2 immune mediators, whereas IL-22 showed no or negative correlations with type 1 and 3 cytokines or proinflammatory mediators in CRSwNP patients. We also observed a significant correlation between SE-specific IgE and IL-22 in NP tissues, although there was no correlation between total IgE and IL-22 levels in NP tissues (Fig. 2B). Moreover, on subgroup analysis according to the IL-5 activity, we found a higher positive association between IL-22 and IL-5 expression in CRSwNP patients who had high IL-5 (> 12.98 pg/mL) activity (r = 0.5904, P = 0.0061) than in those with low IL-5 (≤ 12.98 pg/mL) activity (r = 0.2700, P = 0.0354). Additionally, IL-22 expression in NP tissues was significantly associated with disease severity based on CT scores. In contrast, IL-22 expression positively correlated with various inflammatory mediators (type 1, 2, and 3 inflammatory cytokines and pro-inflammatory mediators) but showed no association with disease extent in CRSsNP patients.

The cellular source of IL-22 in NP
For localization of the cellular sources of IL-22 in eosinophilic NP, we performed double immunofluorescence staining of the NP with abundant eosinophils and mast cell infiltration (Fig. 3). We found that IL-22 was expressed mostly in EPX-positive cells, but not in HNE-
Interleukin-22 and Nasal Polyps

Fig. 1. (A) IL-22 protein levels in the sinonasal tissues of each CRS subtype. (B, C) Factor analysis based on principal component analysis according to the concentration of IL-22 in CRSwNP patients.

IL, interleukin; CRS, chronic rhinosinusitis; CRSsNP, Chronic rhinosinusitis without nasal polyps; CRSwNP, Chronic rhinosinusitis with nasal polyps; UP, uncinate process mucosa; NP, nasal polyps; FAMD, factor analysis of mixed data; IgE, immunoglobulin E; CCL, chemokine (C-C motif) ligand; CXCL, chemokine (C-X-C motif) ligand; ECP, eosinophil cationic protein; MPO, myeloperoxidase; BAFF, B cell activating factor; IFN, interferon; TGF, transforming growth factor.

*P < 0.01, and †P < 0.001 using the Kruskal-Wallis test with Dunn's multiple comparison test.
positive cells. Moreover, a part of tryptase-positive cells also expressed IL-22. Thus, LAD2 cells, a human mast cell line, were cultured and stimulated with IgE, IL-4, IL-13, and SEB to confirm whether human mast cells can produce IL-22 and to identify upstream inducers. IL-22 was released from LAD2 in response to IgE stimulation in a dose-dependent manner, while IL-4, IL-13, and SEB were not (Fig. 4).

**IL-22/IL-22Ra1 signaling pathway in NP**

The IL-22 receptor complex consists of the receptor chains IL-22Ra1 and IL-10Ra2. Additionally, there is a soluble, secreted receptor of IL-22 (IL-22Ra2) which exists as a natural antagonist to IL-22. In this study, IL-22Ra1 was significantly higher in NP than in control and CRSsNP, whereas IL-22Ra2 was not upregulated in CRSwNP, compared with CRSsNP (Fig. 5A and B). The ratio of IL-22Ra1/IL-22Ra2 was the highest in NP (Fig. 5C). These findings imply that the IL-22/IL-22Ra1 axis is mainly activated in NP. Therefore, to confirm what conditions could promote IL-22Ra1 expression, NHBE cells were cultured and stimulated with IL-4, IL-13, and SEB to confirm whether human mast cells can produce IL-22 and to identify upstream inducers. IL-22 was released from LAD2 in response to IgE stimulation in a dose-dependent manner, while IL-4, IL-13, and SEB were not (Fig. 4).

**IL-22/IL-22Ra1 signaling pathway in NP**

The IL-22 receptor complex consists of the receptor chains IL-22Ra1 and IL-10Ra2. Additionally, there is a soluble, secreted receptor of IL-22 (IL-22Ra2) which exists as a natural antagonist to IL-22. In this study, IL-22Ra1 was significantly higher in NP than in control and CRSsNP, whereas IL-22Ra2 was not upregulated in CRSwNP, compared with CRSsNP (Fig. 5A and B). The ratio of IL-22Ra1/IL-22Ra2 was the highest in NP (Fig. 5C). These findings imply that the IL-22/IL-22Ra1 axis is mainly activated in NP. Therefore, to confirm what conditions could promote IL-22Ra1 expression, NHBE cells were cultured and stimulated with IL-4, IL-13, and SEB, IFN-γ (each 100 ng/mL), and poly(I:C). We observed that IL-22Ra1 expression on NHBE cells was up-regulated by poly(I:C) stimulation (Fig. 5D). Moreover, previous studies revealed that the expression of TSLP was induced by poly(I:C) in nasal epithelial cells of NP. Thus, we tested whether the IL-22/IL-22Ra1 axis could promote TSLP expression under poly(I:C) stimulation. NHBE cells stimulated with IL-4, IL-13, or IL-22 alone did not promote TSLP production (Supplementary Fig. S1A); however, when NHBE cells were stimulated with additional poly(I:C) in each experimental protocol, we were able to detect significantly up-regulated TSLP expression (Supplementary Fig. S1B). Furthermore, we found that the combination of IL-13 and poly(I:C) showed much enhanced production of TSLP on 100 ng/mL of IL-22. Treatment with anti-IL-22Ra1 also inhibited IL-22-induced enhancement of TSLP production (Fig. 5E and F).
DISCUSSION

IL-22 is essential not only for the host defense against extracellular pathogens, but also for tissue repair and wound healing. However, uncontrollably continued production of IL-22 can lead to certain diseases. To date, IL-22 has been known to have different functions, depending on the nature of the affected tissue and the local cytokine milieu. However, the role of IL-22 in the allergic airway diseases is still controversial (pro-inflammatory effects vs. anti-inflammatory properties). In this study, we showed that, in patients with CRSwNP, IL-22 expression was positively correlated with type 2 inflammatory cytokines. In addition to eosinophils, mast cells might be the potential source of IL-22 in NP tissues responding to subsequent IgE-mediated signals. The up-regulation of IL-22Ra1 was observed in NP tissues and was induced in NHBE cells by poly(I:C) treatment. Moreover, the enhancement of the IL-22/IL-22Ra1 axis promoted TSLP production in NHBE cells.
Previously, some studies have demonstrated that IL-22 can act a dual role in airway inflammation: anti-inflammatory or pro-inflammatory.\textsuperscript{18,29,30} Our study found that IL-22 expression and its correlation with other inflammatory mediators were different according to the CRS phenotype. Specifically, IL-22 expression was correlated with various inflammatory mediators (type 1, 2, and 3 cytokines and pro-inflammatory mediators) in CRSsNP, whereas there were positive correlations between IL-22 and type 2 cytokines in CRSwNP. Consistent with our findings, one cluster analysis study examined the up-regulation of IL-22 in 2 different phenotypes: the CRSsNP group and the IL-5-high CRS group which consist mostly of CRSwNP patients. They concluded that IL-22 might play different roles according to the cytokine milieu.\textsuperscript{2} Prior studies reported the association of IL-22 with disease severity, demonstrating that significantly higher level of IL-22 expression was detected in serum and sputum of patients with severe asthma than in those with moderate asthma.\textsuperscript{30-32} In accordance with these findings, we also observed that CRSwNP patients showed a significantly positive correlation between IL-22 expression and disease extent based on CT scores.

It is known that IL-22 is produced by immune cells, including helper T cell subsets and innate lymphocytes. Recently, one study described that IL-22 was expressed in CD4+ cells and ECP/EPX+ cells, not in CD68+ cells in the case of CRSwNP patients.\textsuperscript{19} Another study also

Fig. 4. IgE-mediated production and secretion of IL-22 from LAD2 cells. (A) IL-22 was measured by ELISA in the supernatants of LAD2-cell culture stimulated with IgE/SA, IL-4, IL-13, and SEB (n = 3 for each group). (B) IL-22 was measured by ELISA in the supernatants of LAD2-cell culture stimulated in variable concentrations (0.1, 1, or 5 μg/mL) of IgE with SA treatment (n = 3 for each group). (C) Representative double immunostaining (red: tryptase and green: IL-22). Box indicates representative findings (× 200). Scale bar = 50 μm. IL, interleukin; ELISA, enzyme-linked immunosorbent assay; IgE, immunoglobulin E; SEB, Staphylococcal enterotoxin B; SA, streptavidin; Un, unstimulated control.
Fig. 5. IL-22Ra1 expression in CRS and control tissues and in vitro experiment using NHBE cells. (A) IL-22Ra1 mRNA expression in controls and CRS subtypes. (B) IL-22Ra2 mRNA expression in controls and CRS subtypes. (C) The ratio of IL-22Ra1 to IL-22Ra2 mRNA expression in controls and CRS subtypes. (D) Relative mRNA expression of IL-22Ra1 in NHBE cells with stimulation of major cytokines and poly(I:C) (n = 3 for each group). (E) IL-22-induced TSLP production in NHBE cells after type 2 cytokines and poly(I:C) treatment (n = 6 for each group). (F) IL-22-induced TSLP production was reversed by anti-IL-22Ra1 (n = 7 for each group).

IL, interleukin; IL-22Ra, IL-22 receptor subunit alpha; CRS, chronic rhinosinusitis; CRSsNP, chronic rhinosinusitis without nasal polyps; CRSwNP, chronic rhinosinusitis with nasal polyps; UP, uncinate process mucosa; NP, nasal polyps; TSLP, Thymic stromal lymphopoietin; NHBE, normal human bronchial epithelial.

*P < 0.05, †P < 0.01, ‡P < 0.001, and §P < 0.0001 using the Kruskal-Wallis test with Dunn's multiple comparison test.
demonstrated that skin mast cells are a predominant source of IL-22 in patients with psoriasis and atopic dermatitis. Interestingly, in this study, double immunofluorescence staining and LAD2 cell culture revealed that mast cells are another cellular source of IL-22 in NP tissues. Additionally, CRSwNP patients with high IL-5 activity showed a stronger correlation between IL-22 and IL-5 levels than those with low IL-5 activity. Taken together, our findings suggest that IL-22 may play a key role in type 2 airway inflammation in CRSwNP.

It is known that IL-22Ra1 activates the signal transducer and activator transcription-3 signaling pathway, but IL-22Ra1 expression is restricted to cells within epithelial cells, hepatocytes, and acinar cells. A previous study described that nasal epithelial cells obtained from the ethmoid mucosae of CRSwNP are associated with significantly decreased expression of IL-22R1, implying impaired protective function. Some studies on the protective role of IL-22 in airway inflammation demonstrated that IL-22 inhibits the expression of lung epithelial cell-derived cytokines and attenuates the development of allergic airway inflammation. However, in this study, the up-regulated expression of IL-22Ra1 was observed in NP tissues. This implies that IL-22 produced by eosinophils and mast cells act on epithelium via IL-22Ra1. The enhanced IL-22/IL-22Ra1 axis may contribute to the development of nasal polypogenesis by initiating TSLP expression under IL-13 and poly(I:C). However, this is still unclear and should be further investigated when and how the role of IL-22 switches between protective and pathologic ones.

In conclusion, this study indicates that IL-22 may play a pathologic role in patients with CRSwNP. Eosinophils and mast cells may be the major cellular sources of IL-22 in eosinophilic NP tissues. RNA viral infection may mediate up-regulation of IL-22Ra1, activating IL-22/IL-22Ra1 signaling in airway epithelial cells. The enhanced IL-22/IL-22Ra1 axis promotes TSLP production under a type 2 microenvironment in airway epithelial cells, and such a pathway may contribute to the development of NP.

ACKNOWLEDGMENTS

This research was supported by a clinical research grant-in-aid from the Basic Science Research Program through the National Research Foundation of Korea (NRF) funded by the Ministry of Science, ICT and Future Planning (NRF-2018R1D1A3B07040862 to Dong-Kyu Kim and NRF-2019R1A2C2087170 to Dae Woo Kim) and by a fund from the Seoul National University Hospital (05-2016-0020 to Dae Woo Kim). We are grateful to professor Arnold S. Kirshenbaum for providing the cell lines LAD2.

SUPPLEMENTARY MATERIALS

**Supplementary Table S1**
Patient characteristics

Click here to view

**Supplementary Table S2**
Coordinates of principal component analysis for the first 9 principal components

Click here to view
Supplementary Fig. S1

In vitro experiment using NHBE cells. (A) TSLP production in NHBE cells after type 2 cytokine and IL-22 treatment (n = 7 for each group). (B) TSLP production in NHBE cells after treatment of type 2 cytokine and IL-22 in combination with poly(I:C) (n = 7 for each group).

Click here to view

REFERENCES

1. Fokkens WJ, Lund VJ, Mullol J, Bachert C, Alobid I, Baroody F, et al. EPOS 2012: European position paper on rhinosinusitis and nasal polyps 2012. A summary for otorhinolaryngologists. Rhinology 2012;50:1-12.

2. Tomassen P, Vandeplas G, Van Zele T, Cardell LO, Arebro J, Olze H, et al. Inflammatory endotypes of chronic rhinosinusitis based on cluster analysis of biomarkers. J Allergy Clin Immunol 2016;137:1449-1456.e4.

3. Wang X, Zhang N, Bo M, Holtappels G, Zheng M, Lou H, et al. Diversity of Th1 cytokine profiles in patients with chronic rhinosinusitis: a multicenter study in Europe, Asia, and Oceania. J Allergy Clin Immunol 2016;138:1344-53.

4. Liao B, Liu JX, Li ZY, Zhen Z, Cao PP, Yao Y, et al. Multidimensional endotypes of chronic rhinosinusitis and their association with treatment outcomes. Allergy 2018;73:1459-69.

5. Ryu G, Kim DK, Dhong HI, Eun KM, Lee KE, Kong IG, et al. Immunological characteristics in refractory chronic rhinosinusitis with nasal polyps undergoing revision surgeries. Allergy Asthma Immunol Res 2019;11:664-76.

6. Kim DK, Kim JY, Han YE, Kim JK, Lim HS, Eun KM, et al. Elastase-positive neutrophils are associated with refractoriness of chronic rhinosinusitis with nasal polyps in an Asian population. Allergy Asthma Immunol Res 2020;12:42-55.

7. Kim DK, Kang SI, Kong IG, Cho YH, Song SK, Hyun SJ, et al. Two-track medical treatment strategy according to the clinical scoring system for chronic rhinosinusitis. Allergy Asthma Immunol Res 2018;10:490-502.

8. Kim DK, Kim DW. Does inflammatory endotype change in patients with chronic rhinosinusitis? Allergy Asthma Immunol Res 2019;11:353-5.

9. Kim YS, Han D, Kim J, Kim DW, Kim YM, Mo JH, et al. In-depth, proteomic analysis of nasal secretions from patients with chronic rhinosinusitis and nasal polyps. Allergy Asthma Immunol Res 2019;11:691-708.

10. Kim DW. Can neutrophils be a cellular biomarker in Asian chronic rhinosinusitis? Clin Exp Otorhinolaryngol 2019;12:325-6.

11. Wang H, Pan L, Liu Z. Neutrophils as a protagonist and target in chronic rhinosinusitis. Clin Exp Otorhinolaryngol 2019;12:337-47.

12. Sonnenberg GF, Fouser LA, Artis D. Border patrol: regulation of immunity, inflammation and tissue homeostasis at barrier surfaces by IL-22. Nat Immunol 2011;12:383-90.

13. Rutz S, Eidenschenk C, Ouyang W. IL-22, not simply a Th17 cytokine. Immunol Rev 2013;252:116-32.

14. Eyerich K, Eyerich S. Th22 cells in allergic disease. Allergo J Int 2015;24:1-7.

15. Wolk K, Kunz S, Witte E, Friedrich M, Asadullah K, Sabat R. IL-22 increases the innate immunity of tissues. Immunity 2004;21:241-54.
16. Leyva-Castillo JM, Yoon J, Geha RS. IL-22 promotes allergic airway inflammation in epicutaneously sensitized mice. J Allergy Clin Immunol 2019;143:619-630.e7.

17. Chang Y, Al-Alwan L, Risse PA, Rousseau L, Halayko AJ, et al. Th17 cytokines induce human airway smooth muscle cell migration. J Allergy Clin Immunol 2011;127:1046-1053.e1-2.

18. Hirose K, Ito T, Nakajima H. Roles of IL-22 in allergic airway inflammation in mice and humans. Int Immunol 2018;30:413-8.

19. Noyama Y, Okano M, Fujiwara T, Kariya S, Higaki T, Haruna T, et al. IL-22/IL-22R1 signaling regulates the pathophysiology of chronic rhinosinusitis with nasal polyps via alteration of MUC1 expression. Allergol Int 2017;66:42-51.

20. Kim DK, Jin HR, Eun KM, Mo JH, Cho SH, Oh S, et al. The role of interleukin-33 in chronic rhinosinusitis. Thorax 2017;72:635-45.

21. Kim DK, Jin HR, Eun KM, Mutusamy S, Cho SH, Oh S, et al. Non-eosinophilic nasal polyps shows increased epithelial proliferation and localized disease pattern in the early stage. PLoS One 2015;10:e0139945.

22. Kim DW, Kulkarni M, Jo A, Eun KM, Arizmendi N, Tanckowy BP, et al. Cross-talk between human mast cells and epithelial cells by IgE-mediated periostin production in eosinophilic nasal polyps. J Allergy Clin Immunol 2017;139:1692-1695.e6.

23. Shin HW, Kim DK, Park MH, Eun KM, Lee M, So D, et al. IL-25 as a novel therapeutic target in nasal polyps of patients with chronic rhinosinusitis. J Allergy Clin Immunol 2015;135:1476-1485.e7.

24. Diaz-Vazquez C, Torregrosa-Bertet MJ, Carvajal-Urueña I, Cano-Garcinuño A, Fos-Escrivá E, García-Gallego A, et al. Accuracy of ImmunoCAP Rapid in the diagnosis of allergic sensitization in children between 1 and 14 years with recurrent wheezing: the IReNE Study. Pediatr Allergy Immunol 2009;20:604-9.

25. Kim DW, Eun KM, Roh EY, Shin S, Kim DK. Chronic rhinosinusitis without nasal polyps in Asian patients shows mixed inflammatory patterns and neutrophil-related disease severity. Mediators Inflamm 2019;2019:7138643.

26. Kim DK, Eun KM, Kim MK, Cho D, Han SA, Han SY, et al. Comparison between signature cytokines of nasal tissues in subtypes of chronic rhinosinusitis. Allergy Asthma Immuinol Res 2019;11:201-11.

27. Golebski K, van Tongeren J, van Egmond D, de Groot EJ, Fokkens WJ, van Drunen CM. Specific induction of TSLP by the viral rna analogue poly(I:C) in primary epithelial cells derived from nasal polyps. PLoS One 2016;11:e0152808.

28. Tamasauskiene L, Sitkauskiene B. Role of Th22 and IL-22 in pathogenesis of allergic airway diseases: pro-inflammatory or anti-inflammatory effect? Pediatr Neonatol 2018;59:339-44.

29. Sonnenberg GF, Nair MG, Kim TJ, Zaph C, Fouser LA, Artis D. Pathological versus protective functions of IL-22 in airway inflammation are regulated by IL-17A. J Exp Med 2010;207:1293-305.

30. Besnard AG, Sabat R, Dumoutier L, Renaud JC, Willart M, Lambrecht B, et al. Dual role of IL-22 in allergic airway inflammation and its cross-talk with IL-17A. Am J Respir Crit Care Med 2011;183:1153-63.

31. Farfariello V, Amantini C, Nabissi M, Morelli MB, Aperio C, Caprodonzi S, et al. IL-22 mRNA in peripheral blood mononuclear cells from allergic rhinitic and asthmatic pediatric patients. Pediatr Allergy Immunol 2011;22:419-23.

32. Sherkat R, Yazdani R, Ganjalikhani Hakemi M, Homayouni V, Farahani R, Hosseini M, et al. Innate lymphoid cells and cytokines of the novel subtypes of helper T cells in asthma. Asia Pac Allergy 2014;4:212-21.
33. Mashiko S, Bouguermouh S, Rubio M, Baba N, Bissonnette R, Sarfati M. Human mast cells are major IL-22 producers in patients with psoriasis and atopic dermatitis. J Allergy Clin Immunol 2015;136:351-359.e1.
PUBMED | CROSSREF

34. Ramanathan M Jr, Spannhake EW, Lane AP. Chronic rhinosinusitis with nasal polyps is associated with decreased expression of mucosal interleukin 22 receptor. Laryngoscope 2007;117:1839-43.
PUBMED | CROSSREF

35. Takahashi K, Hirose K, Kawashima S, Niwa Y, Wakashin H, Iwata A, et al. IL-22 attenuates IL-25 production by lung epithelial cells and inhibits antigen-induced eosinophilic airway inflammation. J Allergy Clin Immunol 2011;128:1067-1076.e1-6.
PUBMED | CROSSREF

36. Ito T, Hirose K, Saku A, Kono K, Takatori H, Tamachi T, et al. IL-22 induces Reg3γ and inhibits allergic inflammation in house dust mite-induced asthma models. J Exp Med 2017;214:3037-50.
PUBMED | CROSSREF